TScan Therapeutics, Inc.

TCRX · Healthcare

$0.67

Markedsværdi: 45.16M USDUdbytteafkast: —
AdvancedEr det et godt tidspunkt at købe TScan Therapeutics, Inc.? Spørg Copenvest AIFå et Advanced AI-bud på timing, risiko og hvad tracked investorer gør.Spørg Copenvest AI

Indlæser diagram…

Nyheder

Seneste overskrifter for denne aktie

BioPharma Dive4. sep. 2026, 09.00

Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

InvestorsHub2. sep. 2026, 12.30

TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program

GlobeNewswire2. sep. 2026, 11.00

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

Simply Wall St.26. aug. 2026, 19.08

Why Is Amgen (AMGN) Ending Its Crohn's Disease Research Partnership?

Zacks12. aug. 2026, 12.10

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates